A Fundamental Shift in Cancer Care
At Aulos, we’re on a journey to revolutionize cancer patient care through the development of pioneering IL-2 therapeutics that we believe will transform the treatment of solid tumor cancers. We’re taking on the toughest challenges that have limited the effectiveness of IL-2 therapies: the ability to shift IL-2 activity toward immune activation and away from immune suppression, and preventing the toxic side effects of interleukin-2, including vascular leak syndrome and pulmonary edema.
Abstracts and Publications
FEATURE
A Phase 1/2 Dose Escalation and Cohort Expansion Study of AU-007, a Human Monoclonal Antibody (mAb) That Binds to IL-2 and Inhibits CD25 Binding, Plus Low-Dose Aldesleukin in Advanced Solid Tumors
Latest News
AU-007: An Investigational Product Candidate
Aulos has initiated the Phase 2 portion of its Phase 1/2 clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumor cancers. The first expansion cohorts will focus on melanoma and renal cell carcinoma.
